This distinction matters because the best peptide depends on the goal
Side Effects & Safety Mild GI discomfort most common, usually transient in the first week Slight stimulant effect increased energy/alertness, especially early on Headaches occasional, typically mild and dose-related Mild insomnia if taken too late in the day No human clinical safety data all safety information from preclinical studies and community reports No liver toxicity observed in animal studies at therapeutic doses Unknown drug interactions theoretically could interact with NAD+-dependent pathways Core Supplies for This Protocol The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking
Sourcing from reputable suppliers with third-party testing documentation is essential for safety
Disclosure of interest: none Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P1002 - ESOC25-228 PREDIABETES AND DIABETES MELLITUS TYPE 2 ONE YEAR AFTER ACUTE ISCHEMIC STROKE Kurt Mlgg 1,2 , Anel Karisik 1,2 , Lukas Scherer 1,2 , Lucie Buergi 1,2 , Benjamin Dejakum 1 , Silvia Komarek 1 , Julian Granna 2 , Christian Boehme 1 , Raimund Pechlaner 1 , Thomas Tll 1 , Michael Knoflach, Stefan Kiechl 1,2 , Susanne Kaser 3 , Alexander Egger 4 , Andrea Griesmacher 4 , Lukas Mayer-Suess 1 1 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria, 2 VASCage, Centre on Clinical Stroke Research, Innsbruck, Austria, 3 Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria, 4 Central Institute of Clinical Chemistry and Laboratory Medicine, Medical University of Innsbruck, Innsbruck, Austria Background and Aims: The evolution of glycemic status in post-stroke patients remains poorly understood, particularly regarding treatments for type II diabetes mellitus (DM II), such as glucagon-like peptide-1 receptor agonists (GLP-1-RA) and sodium-glucose co-transporter 2 (SGLT-2) inhibitors, which have not been studied in an exclusive post-stroke population
For use in cattle, sheep, swine, horses, dogs and cats
BPC-157 is often described as having anti-inflammatory properties because research suggests it may help support healthy inflammatory responses while promoting tissue repair and recovery
